Rallybio Q3 2024 Earnings Report

Rallybio EPS Results

• Actual EPS: -$2.08
• Consensus EPS: -$2.88
• Beat/Miss: Beat by +$0.80
• One Year Ago EPS: N/A

Rallybio Revenue Results

• Actual Revenue: $0.30 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Rallybio Announcement Details

• Quarter: Q3 2024
• Date: 11/7/2024
• Time: Before Market Opens
• Conference Call Date: Thursday, November 7, 2024
• Conference Call Time: 8:00AM ET

Rallybio (NASDAQ:RLYB) Therapeutics, Inc. (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency. Additional pipeline candidates target lysosomal storage disorders and severe skin fragility syndromes, underscoring the company’s commitment to a precision‐medicine approach. Each program has been selected based on compelling preclinical or early clinical data that suggest a clear path to regulatory milestones and commercialization.

Founded in 2018 and headquartered in New York City, Rallybio completed its initial public offering via a business combination in 2021. The company leverages strategic partnerships, external research collaborations and internal manufacturing capabilities to accelerate development timelines and maintain rigorous quality standards. While Rallybio’s primary operations are based in the United States, its clinical trial network spans North America, Europe and Asia Pacific, reflecting its objective to serve rare disease communities on a global scale.

Rallybio is led by a management team with extensive experience in rare disease research, drug development and regulatory strategy. The company aims to build on its scientific foundation by expanding its pipeline, advancing key assets toward commercialization and fostering collaborations that enhance access to therapies for underserved patient populations worldwide.